Le Lézard
Classified in: Science and technology

Eurofins BioDiagnostics adds BDI Prime Seq, a Genotyping Method Using Next-Generation DNA Sequencing to Accelerate Corn Breeding Efforts

RIVER FALLS, Wis., Dec. 2, 2021 /PRNewswire-PRWeb/ -- Eurofins BioDiagnostics, Inc. (EBDI), a global leader in agriculture and genomics testing, announces the validation of BDI Prime Seq TM as a sequencing based method for testing of maize breeding populations from its River Falls, Wisconsin, location.

The new testing service uses an amplicon based DNA sequencing approach to screen through thousands of corn plants from breeding populations. This method is designed to address the needs of breeders that require rapid solutions to foster development of new maize varieties and accelerate their introduction into the market.

This advancement will be highlighted by EBDI Chief Science Officer Farhad Ghavami, Ph.D, at the upcoming American Seed Trade Association CSS Conference in Chicago, Illinois on December 8, 2021. With over 50 years of on-staff industry experience in both commercial plant breeding and seed production, EBDI stands apart by first seeking to understand breeder needs and then coupling those needs to leading technologies and Eurofins global testing infrastructure.

The new sequencing based method utilizes breakthroughs in multiplexed amplicon PCR coupled with Next Generation DNA Sequencing (NGS) to simultaneously monitor hundreds of genetic positions across the corn genome in large breeding and backcross populations. This tool is highly useful for tracking introgression of novel genetics into elite cultivars, assessing parental contribution in backcross populations and facilitating removal of off-target events from precision gene editing programs. The initial validation set is comprised of a panel of 250 single nucleotide polymorphisms (SNPs) distributed across the maize genome and previously used in microarray genotyping methods. The panel is designed specifically to facilitate marker assisted backcrossing projects and validation results demonstrate the versatility, speed and power of sequencing methods as a robust genotyping solution for molecular assisted applications.

EBDI's River Falls laboratory is an ISO 17025 accredited laboratory and is strategically located near major corn production areas in the Midwest United States. The genomics lab specializes in high throughput DNA extraction and scaled genotyping of a variety of agriculturally important plant and animal species, including Maize, Soybean, Canola and Sorghum.

EBDI is actively engaging with breeding companies as part of an Early Access Program for this new technology. To request more information on how to participate, contact ebdi@eurofinsus.com or visit https://www.eurofinsus.com/agbio

Media Contact

Rick Nipper, Eurofins BioDiagnostics, +1 (720) 745-6367, EBDIAH@eurofinsus.com


SOURCE Eurofins BioDiagnostics

These press releases may also interest you

at 05:31
Ascletis Pharma Inc. (HKEX code: 1672) today announces the dosing of the first patient in the Phase III registration clinical trial of ASC40 combined with bevacizumab for treatment of recurrent glioblastoma (rGBM). ASC40 is an oral, selective...

at 04:05
Cellcom Israel Ltd. announced today that an Extraordinary General Meeting of Shareholders (the "Meeting") of Cellcom Israel Ltd. (the "Company") will be held on Monday, February 28, 2022, at 16:00 p.m. (Israel time), at the offices of the Company,...

at 04:00
Leading Dutch floating engineer Jan Willem Roe?l is internationalising his firm, FlexBase, through the launch of an international office to address global markets, in Singapore. The firm will initially focus on the Southeast Asia and subsequently the...

22 jan 2022
POWERHANDZ is a global athletic training and rehabilitation product tech company transforming the way athletes and patients improve human performance through the combined use of smart sports products, technology and services for any stage of life....

22 jan 2022
The game-changing BLUETTI AC200 power station was initially released to the public on July 1st, 2020. After pulling in a staggering $6.7M US dollars on the crowdfunding platform Indiegogo and having sold tens of thousands of units over the past year,...

22 jan 2022
Natera, Inc. , a leader in personalized genetic testing and diagnostics, today announced new data recently presented on the clinical utility of Signatera, its personalized and tumor-informed molecular residual disease (MRD) test, at the American...

News published on 2 december 2021 at 12:45 and distributed by: